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Background
Relapsing polychondritis (RP) is a disease of unknown
etiology and is characterized by cartilage inflammation.
RP can be isolated or secondary to different diseases (vas-
culitis, myelodysplastic syndrome, rheumatoid arthritis or
systemic lupus erythematosus). While the clinical picture
of RP in adults is well known, RP in childhood remains
poorly described.
Materials and methods
We retrospectively collected data from 10 patients fol-
lowed in three French hospitals for relapsing polychondri-
tis with an age at onset before 18 years.
Results
The mean age for the first symptoms was 8.6 ± 5.7 years
(range 1.8–17). Symptoms included joint pain (10/10),
ocular inflammation (4/9) and chondritis which con-
cerned ears (10/10), nose (6/10) and larynx (5/10). Lab-
oratory tests showed positive ANA in two patients
(>1:160), absence of anticartilage antibodies, and a slight
increase of the erythrocyte sedimentation rate in 5/9
patients (mean = 25 mm) Biopsy was performed in only
two patients and showed perichondritis with eosinophilic
and mononuclear infiltration for Pt2 while it was normal
in Pt7. Treatment mainly consisted in NSAIDs (7/10),
steroids (8/10), and methotrexate (6/10) and more rarely
hydroxychloroquine (2/10), colchicine (1/10), dapsone
(3/10), salazopyrine (2/10), azathioprine (1/10).
Pt 1 died of aortic insufficiency and others presented
recurrent flares with chronic destroying chondritis.
Conclusion
Pediatric RP shares the main clinical features of its adult
counterpart, even if secondary forms seem to be less fre-
quent. Laboratory findings are nonspecific, and biopsies
may be unnecessary. Evolution is marked by chronic
destroying chondritis and could lead to fatal lesions
despite immunosuppressive treatment.
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